| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| (in thousands, except share and per share data) | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Numerator: | | | | | | | | | | | | | | | | |
| Net income (loss) attributable to common stockholders | | $ | 3,915 | | | $ | (8,777 | ) | | $ | (17,600 | ) | | $ | (16,947 | ) |
| Less change in fair value of dilutive common stock warrant liabilities, net of tax | | | (200 | ) | | | — | | | | — | | | | — | |
| Plus interest expense on dilutive convertible notes payable, net of tax | | | 367 | | | | — | | | | — | | | | — | |
| Less change in fair value of derivative liabilities attributable to dilutive convertible notes payable, net of tax | | | (3,368 | ) | | | — | | | | — | | | | — | |
| Net income (loss) attributable to common stockholders – Diluted | | $ | 714 | | | $ | (8,777 | ) | | $ | (17,600 | ) | | $ | (16,947 | ) |
| | | | | | | | | | | | | | | | | |
| Denominator: | | | | | | | | | | | | | | | | |
| Weighted average common shares outstanding | | | 13,079,599 | | | | 10,284,674 | | | | 12,374,096 | | | | 9,549,661 | |
| Weighted average effect of dilutive securities: | | | | | | | | | | | | | | | | |
| Stock options | | | 47,802 | | | | — | | | | — | | | | — | |
| Common stock warrants | | | 6,127 | | | | — | | | | — | | | | — | |
| Convertible notes payable | | | 1,535,214 | | | | — | | | | — | | | | — | |
| Weighted average common shares outstanding – Diluted | | | 14,668,742 | | | | 10,284,674 | | | | 12,374,096 | | | | 9,549,661 | |
| | | | | | | | | | | | | | | | | |
| Net income (loss) per share attributable to common stockholders – basic and diluted | | | | | | | | | | | | | | | | |
| Basic | | $ | 0.30 | | | $ | (0.85 | ) | | $ | (1.42 | ) | | $ | (1.77 | ) |
| Diluted | | $ | 0.05 | | | $ | (0.85 | ) | | $ | (1.42 | ) | | $ | (1.77 | ) |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Convertible notes payable (see Note 8) | | | 62,500 | | | | 1,457,849 | | | | 1,503,596 | | | | 1,457,849 | |
| Common stock warrants (see Note 13) | | | 7,760,247 | | | | 6,818,518 | | | | 7,910,247 | | | | 6,818,518 | |
| Options to purchase common stock (see Note 11) | | | 3,278,643 | | | | 2,681,534 | | | | 3,474,139 | | | | 2,681,534 | |
| Unvested restricted stock awards (see Note 11) | | | — | | | | 36,778 | | | | — | | | | 36,778 | |
| Contingent earn-out shares (see Note 2) | | | — | | | | 329,628 | | | | — | | | | 329,628 | |
| Total shares excluded from diluted net income (loss) per share | | | 11,101,390 | | | | 11,324,307 | | | | 12,887,982 | | | | 11,324,307 | |
|